02.08.19: Crop Science Summer Technology Showcase Day 2 (Jerseyville Agronomy Center), St. Louis, MO, U.S.A.
Crop Science Summer Technology Showcase Day 2 (Jerseyville Agronomy Center), St. Louis, MO, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news
03.06.19: Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019:
New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019In five TRK fusion cancer patients with brain metastases across different tumor histologies, the overall response rate was 60%, with disease control achieved in all patients / In 14 adult and pediatric patients with TRK fusion cancer with primary central nervous system (CNS) tumors (including high grade gliomas), the overall response rate was 36% including two complete responses / 71% of evaluable patients with primary CNS tumors experienced disease control for 24 weeks or more / First pros...
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news
04.06.19: Roadshow West Coast, U.S.A.
Roadshow West Coast, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 3, 2019 Category: Pharmaceuticals Source Type: news
31.05.19: Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Bayer's darolutamide plus androgen deprivation therapy (ADT) delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with non-metastatic castration-resistant prostate canResults of a new post-hoc analysis showed that treatment with darolutamide plus androgen deprivation therapy (ADT) delayed worsening of urinary and bowel symptoms versus placebo plus ADT / Exposure-adjusted incidences of treatment-emergent adverse events (TEAEs), including notably TEAEs associated with androgen receptor (AR) antagonists, were generally similar for daroluta...
Source: Bayer IR Newsfeed: Events - May 31, 2019 Category: Pharmaceuticals Source Type: news
22.05.19: Roadshow Warsaw, Poland
Roadshow Warsaw, PolandLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 21, 2019 Category: Pharmaceuticals Source Type: news
15.05.19: Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019
New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastasesIn children with TRK fusion cancer (n=34), the overall response rate (ORR) was 94% and durable, with median duration of response (DOR) not reached / In adults with TRK fusion cancer (n=74), the ORR was 76% and durable, with median DOR not reached / In evaluable patients with brain metastases (n=5), ORR was 60% / Improvements in quality of life were shown with larotrectinib treatment in both children and ad...
Source: Bayer IR Newsfeed: Events - May 15, 2019 Category: Pharmaceuticals Source Type: news
13.05.19: Bayer statement on jury's decision in California State Glyphosate Trial
Bayer statement on jury's decision in California State Glyphosate Trialmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 14, 2019 Category: Pharmaceuticals Source Type: news
14.05.19: Roadshow Montreal, Canada
Roadshow Montreal, CanadaLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 13, 2019 Category: Pharmaceuticals Source Type: news
13.05.19: Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting:
Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigmData from Bayer's growing oncology portfolio include new analyses on the company's precision oncology treatment larotrectinib, with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other one in patients with brain metastases or primary central nervous system tumors / First detailed presentation of quality of life data from the Phase III ARAMIS trial of the investigational androgen receptor antagonist darolutamide in patients with non-metast...
Source: Bayer IR Newsfeed: Events - May 13, 2019 Category: Pharmaceuticals Source Type: news
13.05.19: Beiersdorf to acquire iconic Coppertone™ brand from Bayer
Beiersdorf to acquire iconic Coppertone™ brand from BayerSignificant expansion of portfolio will advance Beiersdorf's leading position as sun care expert / Beiersdorf delivers first major acquisition under its new C.A.R.E.+ strategy / Divestiture enables Bayer to focus on core OTC businessmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 12, 2019 Category: Pharmaceuticals Source Type: news
14.05.19: Kepler Cheuvreux One-Stop-Shop-Tour, Copenhagen, Scandinavia
Kepler Cheuvreux One-Stop-Shop-Tour, Copenhagen, ScandinaviaLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 10, 2019 Category: Pharmaceuticals Source Type: news
15.05.19: Kepler Cheuvreux One-Stop-Shop-Tour, Stockholm, Scandinavia
Kepler Cheuvreux One-Stop-Shop-Tour, Stockholm, ScandinaviaLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 10, 2019 Category: Pharmaceuticals Source Type: news
15.05.19: Redburn, Toronto Conference, Canada
Redburn, Toronto Conference, CanadaLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 6, 2019 Category: Pharmaceuticals Source Type: news
26.06.19: Deutsche Bank, Issuer & Investor Bond Forum, London, UK
Deutsche Bank, Issuer & Investor Bond Forum, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 6, 2019 Category: Pharmaceuticals Source Type: news
27.06.19: Deutsche Bank, Issuer & Investor Bond Forum, Frankfurt, Germany
Deutsche Bank, Issuer & Investor Bond Forum, Frankfurt, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 6, 2019 Category: Pharmaceuticals Source Type: news
